Literature DB >> 2714049

Pharmacological modification of oxygen affinity improves deformability of deoxygenated sickle erythrocytes: a possible therapeutic approach to sickle cell disease.

A J Keidan1, M C Sowter, C S Johnson, S S Marwah, J Stuart.   

Abstract

1. The formation of polymerized haemoglobin S in sickle cells is critically dependent on the concentration of deoxygenated haemoglobin so that compounds which increase the oxygen affinity of haemoglobin S are potential anti-sickling agents. 2. BW12C [5-(2-formyl-3-hydroxyphenoxy)pentanoic acid] and BWA589C [4-(2-formyl-3-hydroxyphenoxymethyl)benzoic acid] are aromatic benzaldehydes that cause a dose-dependent left-shift of the oxygen saturation curve of haemoglobin S by stabilization of its oxy-(R)-conformation. 3. A 5 micron pore filtration method, which is highly sensitive to polymerization of haemoglobin S, was used to demonstrate a significant improvement in the deformability of deoxygenated sickle erythrocytes at concentrations (0.75-1.5 mmol/l] of BW12C and BWA589C that are achievable in vivo. Both compounds may therefore be of value for the treatment of sickle cell disease. 4. Filtration of sickle cells through pores of 5 microns diameter is a sensitive technique for evaluating the rheological effects of potential anti-sickling compounds.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2714049     DOI: 10.1042/cs0760357

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  3 in total

1.  Pharmacokinetics and pharmacodynamics of tucaresol, an antisickling agent, in healthy volunteers.

Authors:  P E Rolan; A J Mercer; R Wootton; J Posner
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

2.  The pharmacokinetics, tolerability and pharmacodynamics of tucaresol (589C80; 4[2-formyl-3-hydroxyphenoxymethyl] benzoic acid), a potential anti-sickling agent, following oral administration to healthy subjects.

Authors:  P E Rolan; J E Parker; S J Gray; B C Weatherley; J Ingram; W Leavens; R Wootton; J Posner
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

3.  Bone marrow transplantation in sickle cell anaemia.

Authors:  C Vermylen; G Cornu; M Philippe; J Ninane; A Borja; D Latinne; A Ferrant; J L Michaux; G Sokal
Journal:  Arch Dis Child       Date:  1991-10       Impact factor: 3.791

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.